lung support Articles
-
Matrix Gemini Lims at work in Cancer research trials case study
Executive Summary The Roy Castle Lung Cancer Foundation (RCLCF) is a UK wide charity, dedicated to the defeat of lung cancer. It funds basic science research, tobacco control initiatives and work in lung cancer patient information, support and advocacy. RCLCF works towards defeating lung cancer through research, campaigning and education and gives practical and emotional support for patients and ...
-
Gene Therapy for Cystic Fibrosis
What is cystic fibrosis? Cystic fibrosis (CF) is a rare genetic disorder that affects the lungs, digestive system, and other organs. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a protein that regulates chloride ions transport across cell membranes. These mutations cause the CFTR protein to be either absent or not function ...
By Protheragen
-
Understanding the Pulmonary Effects of Inhaled Arsenic Trioxide (ATO)
Arsenic trioxide (ATO) is an inorganic arsenical that poses significant environmental and public health risks due to its toxic nature. While it is widely used in various industrial and medicinal applications, the potential harm caused by intentional or accidental exposure cannot be overlooked. Despite its prevalence, the pulmonary pathology resulting from acute high-dose exposure to ATO has not ...
-
Syndecan-1 promotes lung fibrosis by regulating epithelial reprogramming through extracellular vesicles
Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal lung disease. A maladaptive epithelium due to chronic injury is a prominent feature and contributor to pathogenic cellular communication in IPF. Recent data highlight the concept of a “reprogrammed” lung epithelium as critical in the development of lung fibrosis. Extracellular vesicles (EVs) are potent mediators of cellular ...
-
Cancer Target: Mesothelin
Mesothelin is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein. Its biological function has not yet been clarified, but due to its limited distribution in normal tissues and high expression in some tumor tissues, it is expected to be used in tumor-specific treatment. In existing studies of human epidermoid carcinoma cell lines expressing mesothelin, biodistribution analysis ...
-
A Combination of Ramucirumab Plus Pembrolizumab Lengthened Survival For Some Lung Cancer Patients
A study conducted under the Lung Cancer Master Protocol (Lung-MAP) found that when treated with a combination of ramuzumab (Cyramza) and Keytruda, Patients with advanced NSCLC whose cancer progressed during prior immunotherapy lived significantly longer than when treated with one of the current standard therapies for this cancer. The hazard ratio (80% confidence interval) for overall survival ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you